Needham & Company Reiterates Neurocrine (NBIX) at Hold, "Love Execution on Ingrezza" but Cautious on Future Pipeline Readouts
Tweet Send to a Friend
Needham & Company analyst Ami Fadia reiterated a Hold rating on Neurocrine Bio. (NASDAQ: NBIX), following the company's most recent ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
